|Calculated MW||This protein is fused with 6×his tag at the C-terminus, and has a calculated MW of 28 kDa. The predicted N-terminus is Gly 18. DTT-reduced Protein migrates as 33-40 kDa in SDS-PAGE due to glycosylation.|
|Other Names||KLK13, KLKL4, KLK-13, Kallikrein-13|
|Results||Measured by its ability to cleave the fluorogenic peptide substrate Boc-VPR-AMC. The specific activity is > 150 pmoles / min / µg.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in 20 mM MES, 150 mM NaCl, pH 6.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikrein-13 (KLK13) is also known as Kallikrein-like protein 4 (KLK-L4), is a secreted protein, belongs to the peptidase S1 family and Kallikrein subfamily. KLK-13 contains one peptidase S1 domain. KLK13 is mainly expressed in prostate, breast, testis and salivary gland. KLK13 may be involved in the pathogenesis and / or progression of breast and ovary cancers, and is regarded as a novel cancer biomarker. In addition, KLK13 interacts and forms complexes with several serum protease inhibitors, such as alpha2-macroglobulin, and its expression is regulated by steroid hormones.
Yousef G.M.,et al.J. Biol. Chem. 275:11891-11898(2000).
Komatsu N.,et al.J. Invest. Dermatol. 121:542-549(2003).
Andres A.M.,et al.Genet. Epidemiol. 31:659-671(2007).
Grimwood J.,et al.Nature 428:529-535(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.